Quoin gets FDA feedback that single study may support QRX003 approval

March 25, 2026 8:31 AM

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced results from a Type C meeting with the U.S. Food and Drug Administration regarding ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found